IP Library › Granted Patent US 11,110,181
Granted Patent B2
US 11,110,181 · App. 16/778,361 · Granted Sep 7, 2021

Virus-like particle conjugates for diagnosis and treatment of tumors

Inventors: Elisabet de los Pinos (Brookline, MA); John Todd Schiller (Kensington, MD); Rhonda C. Kines (Washington, DC); John MacDougall (Hingham, MA)
Assignees: Aura Biosciences, Inc.; The United States of America, as represented by the Secretary, Department of Health and Human Services
A61K47/6901A61K39/12A61K41/0057A61K41/0071A61K47/64A61N5/062C07K1/13C07K14/025C07K16/084C07K16/32C12N7/00A61K2039/545A61K2039/585C07K2317/33C07K2317/76C12N2710/20023C12N2710/20033C12N2710/20034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,110,181
App. No.
16/778,361
Granted
Sep 7, 2021
Kind
B2
Abstract

The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.

Claims (14)

1. A tumor-targeting virus-like particle comprising papilloma virus capsid proteins and 50 to 1000 photosensitive molecules conjugated to the capsid proteins, wherein the photosensitive molecules comprise (a) a photosensitive molecule that becomes toxic or produces a toxic molecule upon activation by light and (b) a photosensitive molecule that does not become toxic or produce a toxic molecule upon activation by light.

2. The virus-like particle of claim 1 , wherein the papilloma virus capsid proteins are non-human papilloma virus capsid proteins.

3. The virus-like particle of claim 2 , wherein the non-human papilloma virus capsid proteins comprise L1 capsid proteins.

4. The virus-like particle of claim 3 , wherein the non-human papilloma virus capsid proteins consist of L1 capsid proteins.

5. The virus-like particle of claim 1 , wherein the photosensitive molecules are covalently conjugated to the capsid proteins.

6. A method comprising delivering to a subject a tumor-tropic virus-like particle comprising papilloma virus capsid proteins and 50 to 1000 photosensitive molecules conjugated to the capsid proteins, wherein the photosensitive molecules comprise (a) a photosensitive molecule that becomes toxic or produces a toxic molecule upon activation by light and (b) a photosensitive molecule that does not become toxic or produce a toxic molecule upon activation by light.

7. The method of claim 6 , wherein the subject has a bladder tumor.

8. The method of claim 6 , wherein the papilloma virus capsid proteins are non-human papilloma virus capsid proteins.

9. The method of claim 8 , wherein the non-human papilloma virus capsid proteins comprise L1 capsid proteins.

10. The method of claim 9 , wherein the non-human papilloma virus capsid proteins consist of L1 capsid proteins.

11. The method of claim 6 , wherein the photosensitive molecules are covalently conjugated to the capsid proteins.

12. The method of claim 6 , further comprising activating the photosensitive molecule of (b) at a wavelength of light that permits visualization of the photosensitive molecule of (b).

13. The method of claim 6 , further comprising activating the photosensitive molecule of (a) at a wavelength of light that causes the photosensitive molecule of (a) to become toxic or produce a toxic molecule.

14. The method of claim 6 , wherein the virus-like particle is delivered by injection.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2020
From: DE LOS PINOS, ELISABET; KINES, RHONDA C.; MACDOUGALL, JOHN
To: AURA BIOSCIENCES, INC.
Reel/Frame 052477/0674 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2020
From: SCHILLER, JOHN T.
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 052477/0819 →
Continuity (4)
Continuation 16143147 · Sep 26, 2018
Continuation 15023169
Provisional Application 61879627 · Sep 18, 2013
Related Publication 20200188529A1 · Jun 18, 2020
Cited By (1)
US 12,589,165